Redhill Biopharma Ltd (RDHL) 14.24 $RDHL
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014: 23 Companies and 33 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/p7dbhq/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Biogen Idec Inc. - Cognosci, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genmab A/S - GlaxoSmithKline plc - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Opexa Therapeutics, Inc. - Receptos, Inc. - RedHill Biopharma Ltd. - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - Trophos SA - XenoPort, Inc. Drug Profiles: - laquinimod sodium - dimethyl fumarate - laquinimod sodium - fingolimod hydrochloride - ocrelizumab - interferon beta-1b - daclizumab - RPC-1063 - Epigallocatechin Gallate - GSK-239512 - siponimod - tabalumab - firategrast - ponesimod - plovamer acetate - estriol - imilecleucel-t - olesoxime - ofatumumab - RNS-60 - (rifabutin clarithromycin clofazimine) - diazoxide - MT-1303 - Boswellic Acids - VAY-736 - MEDI-551 - interferon beta-1b pegylated - XP-23829 - Pegylated Interferon-Beta-1b - COG-133 For more information visit http://www.researchandmarkets.com/research/p7dbhq/relapsing
Hypertension - Pipeline Review, H1 2014: 48 Conipanies and 94 Drugs Profiled
M2 - Wed May 07, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h24nbf/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Companies Involved: - AFFiRiS AG - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Ahn-Gook Pharmaceutical Co., Ltd. - Ajinomoto Pharmaceuticals Co., Ltd. - Anacor Pharmaceuticals, Inc. - AngioDesign - Arromax Pharmatech, Co. Ltd. - Bayer AG - BioLineRx, Ltd. - Biocon Limited - Biolink Group AS - CJ CheilJedang Corp. - Cellceutix Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - Cyano Biotech GmbH - Cytokinetics, Incorporated - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - NanoForm Therapeutics Ltd. - Novartis AG - Palatin Technologies, Inc. - QUANTUM GENOMICS Corp. - RedHill Biopharma Ltd. - Sanofi - Takeda Pharmaceutical Company Limited - Toray Industries, Inc. - Torrent Pharmaceuticals Limited Drug Profiles: - azilsartan medoxomil - carvedilol CR - (rosuvastatin telmisartan) - (irbesartan atorvastatin calcium) - (rosuvastatin calcium olmesartan medoxomil) - ZV Combi - pratosartan - carvedilol CR - (rosuvastatin calcium olmesartan medoxomil) - (rosuvastatin valsartan) - CKD-825 - (losartan potassium hydrochlorothiazide amlodipine besylate) - XY-1014-KD-2 - PL-3994 - (atorvastatin calcium losartan potassium) - KD-027 - CS-3150 - (simvastatin Immediate Release amlodipine maleate Delayed Release) - LFF-269 - Potassium Magnesium Citrate - pratosartan - dextromethorphan - QGC-001 - HPT-C/D-3G - (amlodipine besylate losartan potassium) - (simvastatin losartan potassium) - (simvastatin Immediate Release amlodipine maleate Delayed Release) - (candesartan amlodipine besylate) - TAK-272 - MK-7145 IR For more information visit http://www.researchandmarkets.com/research/h2...pertension
RedHill Biopharma to Present at the ChinaBio Partnering Forum 2014
GlobeNewswire - Thu May 01, 6:01AM CDT
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"
, an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs for the treatment of inflammatory and gastrointestinal diseases including cancer and related conditions, today announced that Adi Frish, RedHill's Senior VP Business Development and Licensing, will be presenting at the ChinaBio Partnering Forum 2014, on Wednesday, May 7, 2014, at 15:15 CST. The conference will be held at Kempinski Hotel Suzhou, in Suzhou, China.
RedHill Biopharma Reports Results for the First Quarter of 2014
GlobeNewswire - Wed Apr 30, 10:00AM CDT
Key financial highlights include:
RedHill Biopharma Reports Successful RHB-102 Bioavailability Clinical Trial and Planned Submission of European Marketing Application in Q3/2014
GlobeNewswire - Wed Apr 30, 6:16AM CDT
-- RedHill received positive results from a comparative bioavailability clinical trial which included 20 healthy volunteers
RedHill Biopharma to Host First Quarter 2014 Financial Results Conference Call on May 1, 2014
GlobeNewswire - Tue Apr 29, 9:29AM CDT
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill" , an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary drugs for the treatment of inflammatory and gastrointestinal diseases including cancer and related conditions, today announced that it will host a conference call on Thursday, May 1, 2014, at 9:00 a.m. ET to review the Company's first quarter 2014 financial results and business highlights.
PharmaPoint: Migraine - Current and Future Players 2014
M2 - Tue Apr 29, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5djb5h/pharmapoint) has announced the addition of the "PharmaPoint: Migraine - Current and Future Players" report to their offering. PharmaPoint: Migraine - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Migraine Market. The report identifies and analyses the key companies shaping and driving the global Migraine market. The report provides insight into the competitive Migraine landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by Our team of industry experts. Scope - Investigation of current and future market competition for Migraine - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Migraine sector through market impact analysis, future market scenario and company analysis Key Topics Covered: - Tables & Figures - Introduction - Market Outlook - Current and Future Players - GlaxoSmithKline - AstraZeneca - Merck - Vernalis - Almirall - Pfizer - Zogenix - NuPathe - Allergan - RedHill Biopharma - OptiNose - CoLucid Pharmaceuticals - SUDA - Revance Therapeutics - NeurAxon For more information visit http://www.researchandmarkets.com/research/5d...harmapoint
IntelGenx and RedHill Biopharma Announce Commencement of a Bioavailability Study with Anti-Migraine VersaFilm(TM) Product to Support European Marketing Application Planned for Q3/2014
Newsfile Corp - Mon Apr 28, 7:06AM CDT
full story)
RedHill Biopharma and IntelGenx Announce Commencement of a Bioavailability Study With RHB-103 (Migraine) to Support European Marketing Application Planned for Q3/2014
GlobeNewswire - Mon Apr 28, 7:01AM CDT
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs, together with IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focused on oral drug delivery, today announced the commencement of a comparative bioavailability clinical study comparing RHB-103 to the European reference drug. The study is intended to support the planned submission of a European Marketing Authorization Application ("MAA" for RHB-103, a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines.
IntelGenx and RedHill Biopharma Provide an Update on FDA's Ongoing Review of the NDA for Migraine VersaFilm(TM) Product
GlobeNewswire - Thu Apr 24, 7:27AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX: IGXT) ("IntelGenx" , a Canadian drug delivery company focusing on oral drug delivery, together with RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs, today reported that the U.S. Food and Drug Administration ("FDA" acknowledged receipt of their response to the Complete Response Letter ("CRL" for the VersaFilm(TM) Oral Film Product New Drug Application ("NDA" and has requested further clarifications. The VersaFilm(TM) Oral Film Product is a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines.
RedHill Biopharma and IntelGenx Provide an Update on FDA's Ongoing Review of the NDA for RHB-103 Oral Migraine Film
GlobeNewswire - Thu Apr 24, 7:00AM CDT
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs, together with IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focusing on oral drug delivery, today reported that the U.S. Food and Drug Administration ("FDA" acknowledged receipt of their response to the Complete Response Letter ("CRL" for the RHB-103 New Drug Application ("NDA" and has requested further clarifications. RHB-103 is a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines.
RedHill Biopharma Announces Positive European Scientific Advice Meeting Regarding RHB-102 and Plans to Submit a European Marketing Application
GlobeNewswire - Mon Apr 07, 7:01AM CDT
-- The Company concluded a positive scientific advice meeting with the UK MHRA regarding RHB-102 and plans to submit, during the second half of the year, a European marketing application for the prevention of chemotherapy and radiotherapy-induced nausea and vomiting in cancer patients
RedHill Biopharma to Present at the 26th Annual ROTH Conference
GlobeNewswire - Fri Mar 07, 7:06AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill" , an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary drugs for the treatment of inflammatory and gastrointestinal diseases and related conditions, today announced that Dror Ben-Asher, RedHill's Chief Executive Officer, will be presenting at the 26 Annual ROTH Conference, on Tuesday, March 11, 2014, at 01:00 p.m. PT at the Ritz Carlton, Dana Point, California.
RedHill Biopharma Provides Update on RHB-102 Development and Intellectual Property
GlobeNewswire - Fri Mar 07, 6:00AM CST
-- RHB-102 is a proprietary once-daily oral antiemetic
IntelGenx and RedHill Biopharma Submit Response to FDA CRL for VersaFilm(TM) Product for Migraines
GlobeNewswire - Mon Mar 03, 7:05AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focusing on oral drug delivery, today announced, together with RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage drugs, that they submitted a response to the Complete Response Letter ("CRL" of the U.S. Food and Drug Administration ("FDA" for the New Drug Application ("NDA" for their VersaFilm(TM) Oral Film Product for the treatment of acute migraines.
RedHill Biopharma and IntelGenx Submit Response to FDA CRL for RHB-103 Migraine Oral-Film
GlobeNewswire - Mon Mar 03, 7:00AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage drugs, today announced, together with IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focusing on oral drug delivery, that they submitted a response to the Complete Response Letter ("CRL" of the U.S. Food and Drug Administration ("FDA" for the New Drug Application ("NDA" for RHB-103, an oral thin-film rizatriptan for the treatment of acute migraines.
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014: 23 Companies and 33 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/p7dbhq/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Biogen Idec Inc. - Cognosci, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genmab A/S - GlaxoSmithKline plc - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Opexa Therapeutics, Inc. - Receptos, Inc. - RedHill Biopharma Ltd. - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - Trophos SA - XenoPort, Inc. Drug Profiles: - laquinimod sodium - dimethyl fumarate - laquinimod sodium - fingolimod hydrochloride - ocrelizumab - interferon beta-1b - daclizumab - RPC-1063 - Epigallocatechin Gallate - GSK-239512 - siponimod - tabalumab - firategrast - ponesimod - plovamer acetate - estriol - imilecleucel-t - olesoxime - ofatumumab - RNS-60 - (rifabutin clarithromycin clofazimine) - diazoxide - MT-1303 - Boswellic Acids - VAY-736 - MEDI-551 - interferon beta-1b pegylated - XP-23829 - Pegylated Interferon-Beta-1b - COG-133 For more information visit http://www.researchandmarkets.com/research/p7dbhq/relapsing
Hypertension - Pipeline Review, H1 2014: 48 Conipanies and 94 Drugs Profiled
M2 - Wed May 07, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h24nbf/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Companies Involved: - AFFiRiS AG - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Ahn-Gook Pharmaceutical Co., Ltd. - Ajinomoto Pharmaceuticals Co., Ltd. - Anacor Pharmaceuticals, Inc. - AngioDesign - Arromax Pharmatech, Co. Ltd. - Bayer AG - BioLineRx, Ltd. - Biocon Limited - Biolink Group AS - CJ CheilJedang Corp. - Cellceutix Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - Cyano Biotech GmbH - Cytokinetics, Incorporated - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - NanoForm Therapeutics Ltd. - Novartis AG - Palatin Technologies, Inc. - QUANTUM GENOMICS Corp. - RedHill Biopharma Ltd. - Sanofi - Takeda Pharmaceutical Company Limited - Toray Industries, Inc. - Torrent Pharmaceuticals Limited Drug Profiles: - azilsartan medoxomil - carvedilol CR - (rosuvastatin telmisartan) - (irbesartan atorvastatin calcium) - (rosuvastatin calcium olmesartan medoxomil) - ZV Combi - pratosartan - carvedilol CR - (rosuvastatin calcium olmesartan medoxomil) - (rosuvastatin valsartan) - CKD-825 - (losartan potassium hydrochlorothiazide amlodipine besylate) - XY-1014-KD-2 - PL-3994 - (atorvastatin calcium losartan potassium) - KD-027 - CS-3150 - (simvastatin Immediate Release amlodipine maleate Delayed Release) - LFF-269 - Potassium Magnesium Citrate - pratosartan - dextromethorphan - QGC-001 - HPT-C/D-3G - (amlodipine besylate losartan potassium) - (simvastatin losartan potassium) - (simvastatin Immediate Release amlodipine maleate Delayed Release) - (candesartan amlodipine besylate) - TAK-272 - MK-7145 IR For more information visit http://www.researchandmarkets.com/research/h2...pertension
RedHill Biopharma to Present at the ChinaBio Partnering Forum 2014
GlobeNewswire - Thu May 01, 6:01AM CDT
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"
, an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs for the treatment of inflammatory and gastrointestinal diseases including cancer and related conditions, today announced that Adi Frish, RedHill's Senior VP Business Development and Licensing, will be presenting at the ChinaBio Partnering Forum 2014, on Wednesday, May 7, 2014, at 15:15 CST. The conference will be held at Kempinski Hotel Suzhou, in Suzhou, China. RedHill Biopharma Reports Results for the First Quarter of 2014
GlobeNewswire - Wed Apr 30, 10:00AM CDT
Key financial highlights include:
RedHill Biopharma Reports Successful RHB-102 Bioavailability Clinical Trial and Planned Submission of European Marketing Application in Q3/2014
GlobeNewswire - Wed Apr 30, 6:16AM CDT
-- RedHill received positive results from a comparative bioavailability clinical trial which included 20 healthy volunteers
RedHill Biopharma to Host First Quarter 2014 Financial Results Conference Call on May 1, 2014
GlobeNewswire - Tue Apr 29, 9:29AM CDT
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"
, an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary drugs for the treatment of inflammatory and gastrointestinal diseases including cancer and related conditions, today announced that it will host a conference call on Thursday, May 1, 2014, at 9:00 a.m. ET to review the Company's first quarter 2014 financial results and business highlights. PharmaPoint: Migraine - Current and Future Players 2014
M2 - Tue Apr 29, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5djb5h/pharmapoint) has announced the addition of the "PharmaPoint: Migraine - Current and Future Players" report to their offering. PharmaPoint: Migraine - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Migraine Market. The report identifies and analyses the key companies shaping and driving the global Migraine market. The report provides insight into the competitive Migraine landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by Our team of industry experts. Scope - Investigation of current and future market competition for Migraine - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Migraine sector through market impact analysis, future market scenario and company analysis Key Topics Covered: - Tables & Figures - Introduction - Market Outlook - Current and Future Players - GlaxoSmithKline - AstraZeneca - Merck - Vernalis - Almirall - Pfizer - Zogenix - NuPathe - Allergan - RedHill Biopharma - OptiNose - CoLucid Pharmaceuticals - SUDA - Revance Therapeutics - NeurAxon For more information visit http://www.researchandmarkets.com/research/5d...harmapoint
IntelGenx and RedHill Biopharma Announce Commencement of a Bioavailability Study with Anti-Migraine VersaFilm(TM) Product to Support European Marketing Application Planned for Q3/2014
Newsfile Corp - Mon Apr 28, 7:06AM CDT
full story)
RedHill Biopharma and IntelGenx Announce Commencement of a Bioavailability Study With RHB-103 (Migraine) to Support European Marketing Application Planned for Q3/2014
GlobeNewswire - Mon Apr 28, 7:01AM CDT
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"
, an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs, together with IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focused on oral drug delivery, today announced the commencement of a comparative bioavailability clinical study comparing RHB-103 to the European reference drug. The study is intended to support the planned submission of a European Marketing Authorization Application ("MAA" for RHB-103, a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines. IntelGenx and RedHill Biopharma Provide an Update on FDA's Ongoing Review of the NDA for Migraine VersaFilm(TM) Product
GlobeNewswire - Thu Apr 24, 7:27AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX: IGXT) ("IntelGenx"
, a Canadian drug delivery company focusing on oral drug delivery, together with RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs, today reported that the U.S. Food and Drug Administration ("FDA" acknowledged receipt of their response to the Complete Response Letter ("CRL" for the VersaFilm(TM) Oral Film Product New Drug Application ("NDA" and has requested further clarifications. The VersaFilm(TM) Oral Film Product is a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines. RedHill Biopharma and IntelGenx Provide an Update on FDA's Ongoing Review of the NDA for RHB-103 Oral Migraine Film
GlobeNewswire - Thu Apr 24, 7:00AM CDT
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"
, an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs, together with IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focusing on oral drug delivery, today reported that the U.S. Food and Drug Administration ("FDA" acknowledged receipt of their response to the Complete Response Letter ("CRL" for the RHB-103 New Drug Application ("NDA" and has requested further clarifications. RHB-103 is a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines. RedHill Biopharma Announces Positive European Scientific Advice Meeting Regarding RHB-102 and Plans to Submit a European Marketing Application
GlobeNewswire - Mon Apr 07, 7:01AM CDT
-- The Company concluded a positive scientific advice meeting with the UK MHRA regarding RHB-102 and plans to submit, during the second half of the year, a European marketing application for the prevention of chemotherapy and radiotherapy-induced nausea and vomiting in cancer patients
RedHill Biopharma to Present at the 26th Annual ROTH Conference
GlobeNewswire - Fri Mar 07, 7:06AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"
, an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary drugs for the treatment of inflammatory and gastrointestinal diseases and related conditions, today announced that Dror Ben-Asher, RedHill's Chief Executive Officer, will be presenting at the 26 Annual ROTH Conference, on Tuesday, March 11, 2014, at 01:00 p.m. PT at the Ritz Carlton, Dana Point, California. RedHill Biopharma Provides Update on RHB-102 Development and Intellectual Property
GlobeNewswire - Fri Mar 07, 6:00AM CST
-- RHB-102 is a proprietary once-daily oral antiemetic
IntelGenx and RedHill Biopharma Submit Response to FDA CRL for VersaFilm(TM) Product for Migraines
GlobeNewswire - Mon Mar 03, 7:05AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"
, a Canadian drug delivery company focusing on oral drug delivery, today announced, together with RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage drugs, that they submitted a response to the Complete Response Letter ("CRL" of the U.S. Food and Drug Administration ("FDA" for the New Drug Application ("NDA" for their VersaFilm(TM) Oral Film Product for the treatment of acute migraines. RedHill Biopharma and IntelGenx Submit Response to FDA CRL for RHB-103 Migraine Oral-Film
GlobeNewswire - Mon Mar 03, 7:00AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"
, an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage drugs, today announced, together with IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focusing on oral drug delivery, that they submitted a response to the Complete Response Letter ("CRL" of the U.S. Food and Drug Administration ("FDA" for the New Drug Application ("NDA" for RHB-103, an oral thin-film rizatriptan for the treatment of acute migraines. 
